Infosys Technologies to Develop Data Integration Platform for Elan Pharmaceuticals

The project will involve a "co-creation engagement model" that gives Infosys the option of retaining ownership of co-developed intellectual property, which it can reuse and repackage.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.